Top Markets
Coin of the day
Lexeo Therapeutics, Inc. Common Stock Lexeo Therapeutics, Inc. Common Stock

Lexeo Therapeutics, Inc. Common Stock

LXEO
Peringkat dalam Saham #15117
Lexeo Therapeutics, Inc. is a genetic medicine firm currently in the clinical... Lexeo Therapeutics, Inc. is a genetic medicine firm currently in the clinical development phase, dedicated to addressing both inherited and acquired medical conditions. Its robust pipeline features several gene therapy candidates. These include LX2006, an AAVrh10-based therapy aimed at treating cardiomyopathy linked to Friedreich's ataxia (FA); LX2020, another AAVrh10-based candidate targeting arrhythmogenic cardiomyopathy; LX2021, designed for DSP cardiomyopathy; and LX2022, which focuses on hypertrophic cardiomyopathy (HCM) stemming from TNNI3 mutations. Furthermore, Lexeo is advancing LX1001, an AAVrh10-based gene therapy, alongside LX1020 and LX1021, all intended for individuals homozygous for APOE4. Additionally, LX1004 is under development to treat CLN2 Batten disease. Established in 2017, the company's headquarters are located in New York, New York.
Harga Saham
$4.74
Terakhir disinkronkan: 2026-08-31
Kapitalisasi Pasar
$372.19M
Perubahan (1 hari)
-2.47%
Perubahan (1 tahun)
-1.04%
Negara
US
Perdagangan Lexeo Therapeutics, Inc. Common Stock (LXEO)

Kategori

Riwayat harga saham Lexeo Therapeutics, Inc. Common Stock (LXEO)
Harga penutupan tertinggi: $4.91 pada 2026-08-01

Harga penutupan terendah: $11.06 pada 2023-11-01
Riwayat harga saham Lexeo Therapeutics, Inc. Common Stock dari 2023 hingga 2026
Performa harga saham tahunan
Tahun Performa
2026 (TTM) -31.08%
2025 38.08%
2024 -48.79%
2023 0.00%
Harga saham perusahaan atau pesaing serupa
Perusahaan Harga saham Perubahan 1th% Negara
$544.38 39.22%
US
$1.03K 45.21%
NL
$121.37 -11.93%
AU
$138.80 476.17%
US
$747.04 4.70%
CH